Lataa...
Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris
IMPORTANCE: B-cell depletion with the anti-CD20 antibody rituximab is highly effective for pemphigus vulgaris (PV) treatment. However, most patients experience relapse, and intravenous rituximab infusions are expensive. Therefore, cost-effective anti-CD20 therapies are desirable. OBSERVATIONS: A com...
Tallennettuna:
| Julkaisussa: | JAMA Dermatol |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5897695/ https://ncbi.nlm.nih.gov/pubmed/25133328 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2014.1939 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|